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Translation from bench to bedside is a tremendous chal-lenge for stroke researchers. Effective neuroprotection
from ischemia in humans is elusive despite a number of
encouraging results in the laboratory. However, the lessons
obtained so far might pave the way to better research
strategies and more fruitful translational results. Rapid reper-
fusion within ischemic brain is essential to prevent further
neuronal cell death. What else can be done to minimize brain
damage once blood flow is re-established? Various interven-
tions and drugs can prevent further cell death after reperfu-
sion in animals. However, the challenge remains to be
beneficial in humans. Adequate selection of patients is critical
and there have been advances in identification of biomarkers,
including gene expression signatures1 that may assist to
identify stroke subtypes in patients. Several ongoing stroke
clinical trials (www.strokecenter.org/) are the results of trans-
lation to the clinics of experimental findings. Hypothermia
has provided strong preclinical evidence and several clinical
trials are ongoing worldwide (Controlled Hypothermia in
Large Infarction [CHILI], CHIL, COAST-II, HAIS-SE, and
Mild Hypothermia in Acute Ischemic Stroke trial). Clinical
trials are also assessing molecules that may decrease hemor-
rhagic complications and toxicity of recombinant tissue
plasminogen activator (Desmoteplase in Acute Ischemic
Stroke Trial [DIAS]-3, DIAS-4, TNKilas) and experimental
research is ongoing on this subject.2 Other clinical trials are
focused on therapies that have shown benefits in animals such
as albumin (Alias-2), citicoline (ICTUS), or oxygen (SO2S).
Combination therapies of tissue plasminogen activator and
antioxidants (edaravone–citicoline; deferoxamine; uric acid)
are based on beneficial effects obtained in preclinical studies
with antioxidants in reperfused animals. However, reperfu-
sion injury is not always apparent and treatments targeting
reperfusion injury are not beneficial to all reperfused ani-
mals.3 Therefore, identification of patients with early signs of
reperfusion injury by noninvasive imaging and biomarkers
may be crucial to bring these treatments into successful
randomized controlled clinical trials.
Improvements in animal studies have been made by study-
ing aged individuals4,5 and animals with stroke risk factors or
genetic predisposition to hypertension, diabetes, hyperlipid-
emia, obesity,6 atherosclerosis, inflammation and infection.7
Also, increasing awareness is given to the effects of gender
and sex hormones on the risk and outcome of stroke.8,9
Progress has been made on the concept that not only must
neurons be protected, but also the functionality of the neuro-
vascular unit must be preserved.10 The prominent function of
matrix metalloproteinases in acute brain injury and the
activator effects that tissue plasminogen activator can exert
on matrix metalloproteinases is now recognized. Further-
more, activated matrix metalloproteinase-9 appears to be a
good biomarker that correlates with imaging markers of
blood–brain barrier disruption.11 Ongoing stroke clinical
trials with statins (NeuSTART II, Neu START, and STARS07)
are in part based on the concept of vascular protection and
matrix metalloproteinase inhibition.
Advances in understanding communication between the
brain and periphery are also relevant to stroke research. It is
believed that stroke triggers immunodepression that renders
ischemic animals and patients with stroke more prone to
infection. Infection or strong inflammatory processes before
ischemia exacerbate brain damage in animals,7 and several
drugs that attenuate inflammation12 appear promising in
preclinical studies. The ongoing clinical trial with minocy-
cline (Minocycline to Improve Neurologic Outcome in Stroke
[MINOS]) is mainly based on the anti-inflammatory effects
that this drug has shown in experimental animal models of
stroke. Targeting certain proinflammatory molecules and
innate immune receptors such as interleukin-1b, CCL5,7
HMGB1,13 CD36,14 lipid mediators, complement activation
pathways,15 and factors involved in the coagulation cascade16
are undergoing intense preclinical and clinical research. The
role that alterations in the microcirculation play in brain
damage need to be better explored. How inflammatory
mediators released by brain cells, endothelium, leukocytes,
and platelets17 create procoagulant events in the microvascu-
lature, after recanalization of large vessel occlusion, is under
investigation. The classical view that infiltrating leukocytes
are deleterious is challenged by identification of anti-
inflammatory subtypes of monocytes in patients with stroke,
benefits of regulatory T-cells in ischemic animals, and by
evidence suggesting that leukocyte infiltration is essential to
modify potentially destructive local inflammation after brain
damage.18 The leukocyte responses to brain ischemia are
dynamic and have a specific time course involving phases of
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initiation, phagocytosis, and resolution of inflammation that
paves the way for regenerative processes. Although we must
increase our understanding of the molecular determinants of
these steps, the growing view is that inflammation will have
to be modulated but not fully suppressed.
Experimental findings support functional recovery after
stroke through plasticity phenomena, which can be promoted
with drugs, interventions inducing brain stimulation (eg, en-
riched environment), and stem cells, even in aged rats that still
have regenerative capacity.4 There is an increasing awareness
about the possible relevance of endogenous circulating stem
cells in patients with stroke19,20 and stronger evidence to support
the idea that neurogenesis is activated after stroke in the human
brain.21,22 Animal studies show that subventricular zone-derived
neural progenitor cells migrate along blood vessels toward
ischemic injury sites,23 but we are far from knowing whether
these cells become new neurons integrating into the network.
The available evidence supports the idea that stem cells favor
recovery by promoting an environment that facilitates axonal
regeneration, neurite outgrowth, functional reorganization, and
neurogenesis. Results from the first studies in humans support
beneficial effects of stem cell transplantation,24 and the need for
large trials has been advised after a recent meta-analysis of
current data available in patients with stroke.25 Several cell
therapies are now being used in ongoing stroke trials (eg,
Autologous Cell Therapy, SIVMAS, STEMS2) and are impor-
tant to determine whether the experimental findings will be
translatable to humans.26 Finally, additional studies are needed
to evaluate whether interventions such as electric, electromag-
netic, optical, or other forms of brain stimulation might be
beneficial after stroke. It is likely that the results of ongoing
stroke trials focusing on recovery (eg, Intravenous Thrombolysis
Plus Hypothermia for Acute Treatment of Ischemic Stroke
[ICTUS], ImpACT-24, MACSI, MAG111539, Motor Imagery
for Gait Rehabilitation, Transcranial Direct Current Stimulation,
TRAGAT, Virtual Reality Training Program) will bring some
light to this issue in the near future.
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缺血性卒中的研究 [Desmoteplase in Acute Ischemic 
Stroke Trial, DIAS]-3, DIAS-4, TNKilas)的相关分子
的实验室研究也正在进行 [2]。另外有一些研究致力
于在临床上运用已在动物上获得疗效的药物如白蛋
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